Osilodrostat clinical trials
Also written LCI699 and isturisa.
How each study uses Osilodrostat is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the Osilodrostat studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- 6 Mar 2020 · ISTURISA · NDA 212801 (FDA, Drugs@FDA)
- European Union
- 9 Jan 2020 · Isturisa · EMEA/H/C/004821 (EMA)
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
18 studies that test it; most in 2026 (5)
| Year | Studies |
|---|---|
| 2008 | 3 |
| 2009 | 1 |
| 2011 | 1 |
| 2014 | 1 |
| 2015 | 3 |
| 2016 | 1 |
| 2018 | 1 |
| 2021 | 1 |
| 2025 | 1 |
| 2026 | 5 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 13 · Other 5
Novartis Pharmaceuticals (7) · RECORDATI GROUP (3) · Novartis (3) · University of Basrah (1) · Beckey Trinh (1) · Johns Hopkins University (1) · Mayo Clinic (1) · Laikο General Hospital, Athens (1)
Often tested with
Tested in the same studies.
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 3
Studies that test Osilodrostat.
- Nov 2026Metyrapone Versus Osilodrostat in Patients With Metabolic Autonomous Cortisol Secretion (MACS)Phase 4 · Laikο General Hospital, Athens
- Jan 2027Impact of 1 mg Osilodrostat Therapy on Mild Autonomous Cortisol Secretion (MACS)Phase 2 · Mayo Clinic
- Jul 2027Pharmacokinetic (PK), Pharmacodynamic (PD) and Tolerability of Osilodrostat in Pediatric Patients With Cushing's SyndromePhase 2 · RECORDATI GROUP
Studies
Open first, then newest update. How each study uses Osilodrostat is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 18
- Osilodrostat for Glycemic Control in Mild Autonomous Cortisol Secretion (MACS) With Difficult-To-Control Type 2 Diabetes - A Randomized, Double-Blind, Placebo-Controlled Phase 2 StudyNot yet recruitingPhase 2Beckey TrinhNCT07922148Written as Osilodrostat (Isturisa)
- Osilodrostat in Patients With Hypertension Caused by Hypercortisolaemia Due to Cushing's SyndromeRecruitingPhase 4RECORDATI GROUPNCT07247162Written as Osilodrostat
- Isturisa Treatment in Mild Autonomous Cortisol Secretion( MACS)RecruitingPhase 4Johns Hopkins UniversityNCT07247058Written as Osilodrostat (Isturisa)
- Combination Osilodrostat and Cabergoline in Cushing's DiseaseEnrolling by invitationPhase 4University of BasrahNCT07603466Written as osilodrostat
- Pharmacokinetic (PK), Pharmacodynamic (PD) and Tolerability of Osilodrostat in Pediatric Patients With Cushing's SyndromeRecruitingPhase 2RECORDATI GROUPNCT03708900Written as LCI699
- Impact of 1 mg Osilodrostat Therapy on Mild Autonomous Cortisol Secretion (MACS)RecruitingPhase 2Mayo ClinicNCT07104812Written as Osilodrostat 1 MG
- Metyrapone Versus Osilodrostat in Patients With Metabolic Autonomous Cortisol Secretion (MACS)RecruitingPhase 4Laikο General Hospital, AthensNCT07268222Written as Osilodrostat 1 MG
- Roll-over Study in Patients With Endogenous Cushing's Syndrome for LCI699CompletedPhase 2RECORDATI GROUPNCT03606408Written as osilodrostat
- Efficacy and Safety Evaluation of Osilodrostat in Cushing's DiseaseCompletedPhase 3Novartis PharmaceuticalsNCT02697734Written as osilodrostat
- A Study to Evaluate Efficacy and Safety of LCI699 in Participants With Essential HypertensionCompletedPhase 2Novartis PharmaceuticalsNCT00758524Written as LCI699
- A Study to Evaluate the Efficacy and Safety of LCI699 Compared to Placebo in Participants With Resistant HypertensionCompletedPhase 2NovartisNCT00817635Written as LCI699
- A Study to Evaluate the Effects of LCI699 on Cortisol in Participants With HypertensionCompletedPhase 2NovartisNCT00817414Written as LCI699
- Safety and Efficacy of LCI699 in Cushing's Disease PatientsCompletedPhase 2Novartis PharmaceuticalsNCT01331239Written as LCI699
- Safety and Efficacy of LCI699 for the Treatment of Patients With Cushing's DiseaseCompletedPhase 3Novartis PharmaceuticalsNCT02180217Written as osilodrostat
- A Phase 1 Study of Osilodrostat (LCI699) in Healthy Volunteers and Subjects With Impaired Hepatic FunctionCompletedPhase 1Novartis PharmaceuticalsNCT02372084Written as osilodrostat
- A Phase I Study of Osilodrostat (LCI699) in Healthy Volunteers and Subjects With Impaired Renal FunctionCompletedPhase 1Novartis PharmaceuticalsNCT02399202Written as osilodrostat
- Study of Efficacy and Safety of Osilodrostat in Cushing's SyndromeCompletedPhase 2Novartis PharmaceuticalsNCT02468193Written as Osilodrostat
- Proof-of-concept for the Aldosterone Synthase Inhibitor LCI699 in Patients With Primary HyperaldosteronismCompletedPhase 2NovartisNCT00732771Written as LCI699
What changed recently
From the registry's own updates since Oct 17, 2026.
Started recruiting1
Codes
What other systems call Osilodrostat · ClinicalTrials.gg INT005732
- MeSH (NLM) C553306OsilodrostatConfirmed ClinicalTrials.gov, NLM
- UNII (FDA) 5YL4IQ1078OSILODROSTATConfirmed FDA, NLM, Wikidata
- RxNorm 2286252Confirmed FDA, Wikidata
- Wikidata Q27088216osilodrostatConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C131535OsilodrostatOne source FDA
- DrugBank DB11837One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C553306 | Osilodrostat | Confirmed ClinicalTrials.gov, NLM |
| UNII (FDA) | 5YL4IQ1078 | OSILODROSTAT | Confirmed FDA, NLM, Wikidata |
| RxNorm | 2286252 | — | Confirmed FDA, Wikidata |
| Wikidata | Q27088216 | osilodrostat | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C131535 | Osilodrostat | One source FDA |
| DrugBank | DB11837 | — | One source Wikidata |
Also registered as osilodrostat phosphate (UNII Y6581YAW9V · RxNorm 2286253).
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.